Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and
Full Year 2012 Financial Results
Conference Call Scheduled for March 15, 2013 at 8:30 am ET
SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain, today announced it
will release financial results for the fourth quarter and full year ended
December 31, 2012, before the market opens on Friday, March 15, 2013, and will
hold a conference call on this day at 8:30 a.m. ET (5:30 a.m. PT), to discuss
these financial results and provide a company update.
To access the live webcast please visit the Company's Investor Relations
website at ir.zogenix.com, and to participate, please dial (866) 202-3048
(U.S.) or (617) 213-8843 (International); participant passcode: 73489853.
The conference call will be hosted by Chief Executive Officer Roger L. Hawley,
President and Chief Operating Officer Stephen J. Farr, Ph.D., and Executive
Vice President and Chief Financial Officer Ann Rhoads.
A replay of the conference call will be available beginning March 15, 2013 at
10:30 a.m. ET (7:30 a.m. PT) until March 22, 2013, by dialing (888) 286-8010
(U.S.) or (617) 801-6888 (International); passcode: 78479681. A replay of the
webcast will also be accessible on the Investor Relations website for one
month, through April 15, 2013.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville,
California, is a pharmaceutical company commercializing and developing
products for the treatment of central nervous system disorders and pain.
Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection)
Needle-free Delivery System, was launched in January 2010 for the acute
treatment of migraine and cluster headache. Zogenix's lead investigational
product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral,
extended-release formulation of various strengths of hydrocodone, without
acetaminophen, intended for administration every 12 hours for around the clock
management of moderate to severe chronic pain. In May 2012, Zogenix submitted
to the FDA a New Drug Application for Zohydro ER. Zogenix's second
investigational product candidate, Relday™, is a proprietary, long-acting
injectable formulation of risperidone for the treatment of schizophrenia; an
investigational new drug application was submitted to the FDA in May 2012. For
additional information, please visit www.zogenix.com.
Zack Kubow | The Ruth Group
646.536.7020 | email@example.com
Caitlin Cox | The Ruth Group
646.536.7033 | firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.